Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 97-108, October 2010

The Antiphospholipid Syndrome as a Neurological Disease

  • Yoav Arnson, MD

      Affiliations

    • Department of Medicine D, Meir Medical Center, Kfar Saba and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • ,
  • Yehuda Shoenfeld, MD

      Affiliations

    • Department of Medicine B and Center for Autoimmune Diseases, and Tel Aviv University, Sackler Faculty of Medicine, Sheba Medical Center, Tel Hashomer, Israel
  • ,
  • Eisen Alon, MD

      Affiliations

    • Department of Medicine D, Meir Medical Center, Kfar Saba and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • ,
  • Howard Amital, MD, MHA

      Affiliations

    • Department of Medicine D, Meir Medical Center, Kfar Saba and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationAddress reprint requests to: Howard Amital, MD, MHA, Head of Department of Medicine D, Meir Medical Center, Tshernichovsky 59, Kfar Saba, 95847, Israel

published online 14 July 2009.

Objectives

To examine currently known and additional potential neurological manifestations of the antiphospholipid syndrome (APS) and to discuss current and experimental therapeutic options in light of the present knowledge of the disease mechanism.

Methods

The PubMed database was searched for articles published between the years 1980 and 2008 for keywords referring to APS and several neurological conditions. Relevant English language articles were reviewed.

Results

APS is characterized by diverse neurological manifestations. These include cerebral ischemic events, epilepsy, dementia, cognitive deficits, headaches, psychiatric disorders, chorea, multiple sclerosis-like, transverse myelitis, and ocular symptoms. Some of the symptoms can be associated with ischemia; however, other mechanisms that could lead to similar outcomes have been described, such as direct binding of antiphospholipid antibodies to neural tissue. Current treatment guidelines concern cerebrovascular events only. We propose several different therapeutic options related to the autoimmune nature of the syndrome.

Conclusion

Neurological manifestations in APS are diverse and may be confused with other neurologic syndromes. This information is important for the proper diagnosis and management of patients. Experimental therapeutic alternatives expand the treatment options for patients and physicians.

Keywords: APS, antiphospholipid antibodies, migraines, seizures, cerebrovascular accidents

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0049-0172(09)00055-9

doi:10.1016/j.semarthrit.2009.05.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 97-108, October 2010